# Cereius

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cereius

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.cereius.io
- Total disclosed funding: $6.5M
- Latest round: Series A (Jul 24, 2018)
- Investors on record: 1

## About

Cereius Inc. is a US-based technology company that delivers innovative software solutions aimed at enhancing operational efficiency across industries, focusing on enterprise resource planning (ERP) tools that integrate with client systems.Cereius Inc., founded in 2017 and headquartered in Durham, US, specializes in technology-driven software solutions. The company has completed 4 deals to date, with the most recent deal occurring on June 22, 2023. Cereius's latest funding round was a Venture Debt round in which they raised USD 0.50 mn from North Carolina Biotechnology Center, bringing their total amount raised to USD 6.50 mn.Cereius is a technology-driven company specializing in innovative software solutions designed to enhance operational efficiency across various industries. Their core product offerings include a suite of enterprise resource planning (ERP) tools that integrate seamlessly with client systems, facilitating real-time data analysis and streamlined workflow management. These tools are aimed at addressing challenges such as inventory management, supply chain optimization, and financial tracking, with products released in the past two years targeting small to medium-sized enterprises (SMEs) and larger corporations in North America and Europe.Cereius generates revenue through a subscription-based model, allowing clients to access their software solutions on a tiered pricing structure. Customers typically engage in annual contracts, with various service tiers available. The company's flagship ERP system is a key revenue driver, as clients often enter long-term agreements that secure recurring income, fostering client retention and enabling scalability in alignment with evolving user demands.Cereius aims to leverage its recent funding to develop new products and expand into new geographic markets. Following the acquisition by Solve Therapeutics in June 2023, the company anticipates launching innovative features in its ERP offerings to enhance customer satisfaction. Plans include targeting further expansion into Europe and Asia by mid-2024, capitalizing on increasing demand for digitized operational processes in these regions.

## Funding rounds

- Series A, Jul 24, 2018, $6.5M — Mission Biocapital

## Investors

- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A